BioCryst Pharmaceuticals, Inc. revenue breakdown overview

BioCryst Pharmaceuticals, Inc. revenue for the last year amounted to 450.71 M USD, the most of which — 450.71 M USD — came from its highest performing source at the moment, Oral Small-molecule and Injectable Protein Therapeutics, the year earlier bringing 331.41 M USD. The greatest contribution to the revenue figure was made by United States — last year it brought BioCryst Pharmaceuticals, Inc. 385.96 M USD, and the year before that — 288.36 M USD.